Characteristics of IL-3 Derived and IL-3 Dependent Lymphocyte Cell Lines

  • Andrew J. Hapel
  • John C. Lee
  • Joel Greenberger
  • James N. Ihle
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 149)


Interleukin-3 (IL-3) is a recently described lymphokine which induces expression of the enzyme 20 alpha hydroxysteroid dehydrogenase (20αSDH) in spleen cells of nu/nu mice (1). In normal mice 20αSDH is associated with cortisone-resistant Thy 1+ cells (1–3) whereas cortisone sensitive Thy 1+ cells in the thymus are terminal deoxynucleotidyl transferase (TdT) positive and 20αSDH negative (4–6). IL-3 induces proliferation of Thy lLyt 1- 2 spleen cells, but has no effect on thymocytes (1). The factor is found in conditioned media (CM) from: a) mixed leucocyte reactions; b) antigen stimulated immune lymphocytes; c) PHA or Con A stimulated lymphocytes; and d) the WEHI-3 cell line. In the first three cases IL-3 is produced by a Thy 1+ Lyt 1+ 2- cell. Conditioned media from in vitro stimulated lymphocytes have been used to support the growth of cytotoxic Thy 1+ Lyt 1- 2+ T cell lines due to the presence of IL-2 (7, 8). Recently, Nabel et al. (9) have demonstrated that CM from Con A stimulated lymphocytes will support the growth of several distinct phenotypes of “T” lymphocytes. One interpretation of this finding is that IL-2 supports the growth of many phenotypically different subsets of T cells.


Conditioned Medium Terminal Deoxynucleotidyl Transferase Splenic Lymphocyte Stimulate Lymphocyte Cell Surface Phenotype 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J. N. Ihle, L. Pepersack, and L. Rebar. J. Immunol. 126:2184 (1981).PubMedGoogle Scholar
  2. 2.
    Y. Weinstein, H.R. Linder, and B. Eckstein. Nature 266:632 (1977).PubMedCrossRefGoogle Scholar
  3. 3.
    L. Pepersack, J.C. Lee, R. McEwan, and J.N. Ihle. J. Immunol. 124:279 (1980).PubMedGoogle Scholar
  4. 4.
    R. Barton, I. Goldschneider, and F.J. Bollum. J. Immunol. 116:462 (1976).PubMedGoogle Scholar
  5. 5.
    M.S. Coleman, J.J. Hutton, and F.J. Bollum. Biochem. Biophys. Res. Commun. 58:1104 (1974).PubMedCrossRefGoogle Scholar
  6. 6.
    A.E. Silverstone, H. Cantor, G. Goldstein, and D. Baltimore. J. Exp. Med. 144:543 (1976).PubMedCrossRefGoogle Scholar
  7. 7.
    S. Gillis, and K.A. Smith. J. Exp. Med. 146:468 (1977).PubMedCrossRefGoogle Scholar
  8. 8.
    D.A. Morgan, F.W. Ruscetti, and R.C. Gallo. Science 193:1007 (1976).PubMedCrossRefGoogle Scholar
  9. 9.
    G. Nabel, M. Fresno, A. Chersman, and H. Cantor. Cell 23:19 (1981).PubMedCrossRefGoogle Scholar
  10. 10.
    A.J. Hapel, J.C. Lee, W.L. Farrar, and J.N. Ihle. Cell 25:179 (1981).PubMedCrossRefGoogle Scholar
  11. 11.
    J.S. Greenberger. J. Supramolec. Struct. 13:501 (1980).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Andrew J. Hapel
    • 1
  • John C. Lee
    • 1
  • Joel Greenberger
    • 2
  • James N. Ihle
    • 1
  1. 1.NCI-Frederick Cancer Research FacilityFrederickUSA
  2. 2.Sidney Farber Cancer CenterBostonUSA

Personalised recommendations